Kadcyla


Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) is approved by the U.S. Food and Drug Administration to treat HER2-positive metastatic breast cancer that has previously been treated with Herceptin (chemical name: trastuzumab) and a taxane chemotherapy.

In this section you can learn more about:

To connect with others with HER2-positive breast cancer, join the Breastcancer.org Discussion Board HER2-Positive Breast Cancer forum.

Or, to connect with others diagnosed with metastatic breast cancer, join the Breastcancer.org Discussion Board Stage IV and Metastatic Breast Cancer ONLY forum.

Was this resource helpful?

Yes No
Evergreen-donate
Back to Top